4 D Molecular Therapeutics, Inc. FDMT
We take great care to ensure that the data presented and summarized in this overview for 4D Molecular Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FDMT
View all-
Black Rock Inc. New York, NY4.9MShares$17.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$16.6 Million0.41% of portfolio
-
Goldman Sachs Group Inc New York, NY4.27MShares$15.5 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.95MShares$10.7 Million2.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.86MShares$10.4 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.67MShares$9.69 Million0.56% of portfolio
-
Janus Henderson Group PLC London, X02.25MShares$8.18 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.86MShares$6.76 Million0.0% of portfolio
-
Novo Holdings Hellerup, G71.5MShares$5.45 Million0.68% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.42MShares$5.16 Million0.0% of portfolio
Latest Institutional Activity in FDMT
Top Purchases
Top Sells
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Insider Transactions at FDMT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2024
|
Ra Capital Management, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
535,000
-10.49%
|
-
|
|
Nov 08
2024
|
Bvf Partners L P |
SELL
Other acquisition or disposition
|
Direct |
5,680,000
-76.69%
|
-
|
|
Sep 16
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-6.87%
|
$8,000
$16.33 P/Share
|
|
Sep 16
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+6.43%
|
$3,000
$6.49 P/Share
|
|
Aug 19
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-6.87%
|
$7,500
$15.0 P/Share
|
|
Aug 19
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+6.43%
|
$3,000
$6.49 P/Share
|
|
Jul 16
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,750
-20.51%
|
$47,250
$27.11 P/Share
|
|
Jul 16
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,750
+9.6%
|
$12,250
$7.27 P/Share
|
|
Jul 11
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,996
-22.74%
|
$49,900
$25.0 P/Share
|
|
Jul 11
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,996
+18.53%
|
$29,940
$15.78 P/Share
|
|
Jul 10
2024
|
David Kirn Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,923
-1.21%
|
$284,306
$22.49 P/Share
|
|
Jul 10
2024
|
David Kirn Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,923
+0.6%
|
$193,845
$15.1 P/Share
|
|
Jul 01
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,248
-70.98%
|
$89,208
$21.36 P/Share
|
|
Jul 01
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,248
+31.51%
|
$29,736
$7.27 P/Share
|
|
Jun 24
2024
|
David Kirn Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,930
-1.21%
|
$297,390
$23.1 P/Share
|
|
Jun 24
2024
|
David Kirn Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,930
+1.19%
|
$181,020
$14.42 P/Share
|
|
Jun 17
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,750
-50.19%
|
$40,250
$23.71 P/Share
|
|
Jun 17
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,750
+22.33%
|
$12,250
$7.27 P/Share
|
|
May 16
2024
|
Scott Bizily Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,750
-28.99%
|
$43,750
$25.55 P/Share
|
|
May 16
2024
|
Scott Bizily Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,750
+22.33%
|
$12,250
$7.27 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 40.1K shares |
|---|
| Other acquisition or disposition | 6.22M shares |
|---|---|
| Open market or private sale | 40.1K shares |